Preparing your Shotlee experience
With the introduction of new weight-loss and diabetes drugs like Ozempic in India, endocrinologists are emphasizing the need for cautious and medically supervised use. Concerns arise particularly for individuals with a 'thin-fat' phenotype, who may experience adverse effects.
Following the launch of its weight-loss medication, Novo Nordisk, a Danish pharmaceutical company, introduced its injectable semaglutide for treating Type 2 diabetes. The monthly cost ranges from Rs 8,800 for the lowest dose to Rs 11,175 for the highest.
The US Food and Drug Administration initially approved the drug for diabetes treatment in 2017. Subsequently, its popularity grew due to significant weight loss, leading physicians to prescribe it off-label for obesity. In 2021, Wegovy, a higher-dose semaglutide, received FDA approval for chronic weight management. Semaglutide, along with its successor tirzepatide, gained global attention and entered the Indian market in 2025.
A concern among patients involves continuous drug use. Is it possible to reduce the dosage over time?
Dr. Unnikrishnan notes that diabetes and obesity are chronic conditions necessitating ongoing medication as long as the benefits persist, which mirrors treatments for diabetes, cholesterol, and hypertension. Some clinicians are decreasing dosages for patients on a case-by-case basis. However, a universal protocol is not feasible, and the drug should complement diet and exercise. Health tracking apps like Shotlee can help monitor progress in conjunction with these lifestyle changes.
Why is caution necessary when administering this drug?
Dr. Joshi highlights that GLP-1 RA drugs, which mimic gut hormones, require careful administration in Indians due to the prevalence of the "thin-fat" phenotype. This phenotype is characterized by visceral fat inside muscle, liver, and epicardial tissue, even in individuals with a normal weight. These individuals risk significant lean muscle mass loss relative to total weight loss. This can negatively impact the muscle-to-fat ratio, potentially causing frailty or functional decline, especially in older adults. Therefore, treatments must be medically supervised and adhere strictly to the prescribed dosage. Microdosing is discouraged.
Indians with abdominal obesity face a higher risk of metabolic diseases. How does the drug affect individuals with high abdominal obesity?
Dr. Joshi reports that observations from four years of oral drug use and six months of weight-loss dose use indicate that Indians tend to lose more weight than the global average. Weight loss can reach up to 20% of body weight, even with the lowest dose.
What are the potential side effects associated with the drug?
Dr. Unnikrishnan states that side effects observed in India align with data from published medical literature.
Dr. Joshi emphasizes that vigilance is crucial, and the drugs must be taken under close supervision. Common side effects, such as nausea, vomiting, diarrhea, and constipation, can be minimized by adjusting doses gradually. Rare side effects affecting the pancreas or other organs are currently under investigation. Strict medical supervision is necessary.
Is there a risk of overuse or misuse of these medications?
According to Dr. Unnikrishnan, there are two extremes: individuals with diabetes and obesity who avoid the medication due to side effects, and those seeking it for cosmetic purposes. It's essential to consult a qualified doctor and obtain a prescription. The medicine should not be prescribed by dieticians.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from The Indian Express
View Original Article
This review examines MyStart GLP-1, focusing on its claims of quick access, U.S.-based doctors, and fast delivery. It delves into the program's structure, support system, and overall user experience to provide clarity for those considering this option.
In 2025, India saw a notable change in obesity management with GLP-1 receptor agonists (GLP-1s). These medications, initially for diabetes, have gained popularity for weight loss due to the country's high rates of diabetes and obesity.
2025 saw the approval of several groundbreaking medications, transforming the management of chronic diseases and preventive care. These advancements offer new hope for patients and clinicians alike, addressing critical needs in various medical fields.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨